Please assess the completion status of the following clinical trial:

Trial Title: Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women 18-85 years of age.~2. Scheduled for elective knee or hip arthroplasty with spinal anesthesia.~Exclusion Criteria:~1. Creatinine \>1.50 mg/dl.~2. History of clinically important current depression or currently on any prescribed anti-depressant medication.~3. Previously enrolled in any Xenoport trial.~4. Use of gabapentin or gabapentinoids (Lyrica, Horizant, Neurontin or Gralise) within one month.~5. Allergy to gabapentin or gabapentinoids (Lyrica, Horizant, Neurontin or Gralise).~6. Women who are pregnant or breastfeeding.~7. History of seizure disorder within the last one-year or taking medications for seizures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin enacarbil (Type: EXPERIMENTAL): Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days
- Placebo (Type: PLACEBO_COMPARATOR): Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).